510(k) device
TearCare System
Sight Sciences, Inc. · Eyelid Thermal Pulsation System (ORZ, Class II) · First FDA decision Dec 21, 2021, newest Aug 18, 2026Dry eye
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
9
Naming "TearCare"
MAUDE reports
4
Brand "TearCare", since 2015
PubMed studies
20
Mentioning "TearCare"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TearCare System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- TearCare System510(k)
K262479 · Decided Aug 18, 2026 · 29 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "TearCare", any status and sponsor, newest update first.
Sight Sciences, Inc.Not on our public-company list
NCT07365735 · 21 participants · Start Mar 17, 2026 · Primary completion May 19, 2026
Device: localized heat therapy · For: Meibomian Gland Dysfunction (Disorder)
Sites: Brecksville, Ohio
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TearCare", and for the whole product code for context.
This brand
4 reports: 0 malfunction, 4 injury, 0 death
Whole product code ORZ
35 reports: 5 malfunction, 29 injury, 0 death
Newest reports for this brand
- TEARCAREInjury
MW5164267 · Received Jan 2, 2025 · Event dated Jan 6, 2022
Device type: Eyelid Thermal Pulsation System (ORZ)
Patient problem as coded: Skin Discoloration
3 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TearCare"[tiab]. The summary above synthesizes these.
- Quintessence of currently approved and upcoming treatments for dry eye disease.
Patil S, Sawale G, Ghuge S, et al. · Graefes Arch Clin Exp Ophthalmol · 2025Review
- Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis.
Ben Ephraim Noyman D, Chan CC, Teichman JC, et al. · Ophthalmol Ther · 2025
- A Single-center Retrospective Trial of a Blink-assisted Eyelid Device in Treating the Signs and Symptoms of Dry Eye.
Chester T · Optom Vis Sci · 2021Research Support, Non-U.S. Gov't
- A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease.
Holland EJ, Loh J, Bloomenstein M, et al. · Clin Ophthalmol · 2022
- Technological Interventions for Dry Eye Disease: A Systematic Review and Random-Effects Network Meta-analysis of 3-Month Outcomes.
Noyman DBE, Chan CC, Teichman JC, et al. · Ophthalmol Ther · 2026
- TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial.
Gupta PK, Holland EJ, Hovanesian J, et al. · Cornea · 2022Comparative Study, Multicenter Study
- TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis.
Lighthizer N, Schwertz BK, Chester T, et al. · Expert Rev Pharmacoecon Outcomes Res · 2025Comparative Study
- In-office thermal systems for the treatment of dry eye disease.
Beining MW, Magnø MS, Moschowits E, et al. · Surv Ophthalmol · 2022Review, Research Support, Non-U.S. Gov't
- Impact of TearCare on Reading Speed in Patients with Dry Eye Disease.
Feng Y, Venkateswaran N, Steele A, et al. · Clin Ophthalmol · 2024
- Localized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time.
Chester T, Ferguson T, Chester E · Optom Vis Sci · 2023
- TearCare® system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare® treatment on subjects with dry eye disease.
Badawi D · Clin Ophthalmol · 2019
- A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA) [Response To Letter].
Ayres BD, Bloomenstein MR, Loh J, et al. · Clin Ophthalmol · 2024Comment, Letter
Other devices of this type
Also filed under product code ORZ.
- LipiFlow Thermal Pulsation SystemTearscience, Inc. · 510(k) 2019
- TearCare MGX SystemSight Sciences, Inc. · 510(k) 2026
- Tixel i (TXLI0001)Novoxel , Ltd. · 510(k) 2024
- Systane iLux2Tear Film Innovations, Inc. · 510(k) 2020
- iLux Instrument, iLux DisposableTear Film Innovations, Inc. · 510(k) 2017
- Lipflow Thermal Pulsation System (Formerly Manual Mini System)Tearscience, Inc. · De Novo 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.